Editorial: Epidemic-Assistance Investigations by the Centers for Disease Control and Prevention—The First 60 Years

Por O'Brien, Thomas R.
Publicado em 2011

What Have We Learned from Studies of IFN-λ Variants and Hepatitis C Virus Infection?

Por O'Brien, Thomas R., Jackson, Sarah S.
Publicado no J Interferon Cytokine Res (2019)

Recent Decline in Hepatocellular Carcinoma Rates in the United States

Por Shiels, Meredith S., O’Brien, Thomas R.
Publicado no Gastroenterology (2020)

IL28B-Genotype Testing Now and in the Era of Direct-Acting Antiviral Agents

Por Morgan, Timothy R., O’Brien, Thomas R.
Publicado em 2010

Reply: Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C

Por O’Brien, Thomas R., Pfeiffer, Ruth M.
Publicado no Open Forum Infect Dis (2015)

Population Genetics and Comparative Genetics of CLDN1, a Gene Involved in Hepatitis C Virus Entry

Por Bekker, Vincent, O’Brien, Thomas R., Chanock, Stephen
Publicado em 2009

The role of genetics in hepatic fibrosis amongst HCV patients

Por Park, Heiyoung, O’Brien, Thomas R., Rehermann, Barbara
Publicado no Hepatology (2018)

Possible Role of Hepatitis D Virus in Severe Hepatitis Related to Hepatitis B Virus Reactivation After Therapy for Chronic Hepatitis C

Por Mahale, Parag, Glenn, Jeffrey S., O’Brien, Thomas R.
Publicado no Ann Intern Med (2017)

Interferon-lambda and therapy for chronic hepatitis C virus infection

Por Donnelly, Raymond P., Dickensheets, Harold, O'Brien, Thomas R.
Publicado em 2011

What makes the hepatitis C virus evolve?

Por O'Brien, Thomas R, Hartmann, Rune, Prokunina-Olsson, Ludmila
Publicado no eLife (2019)

IFNL4 Genotype is Associated with Virologic Relapse After 8-Week Treatment with Sofosbuvir, Velpatasvir and Voxilaprevir

Por O’Brien, Thomas R., Kottilil, Shyam, Pfeiffer, Ruth M.
Publicado no Gastroenterology (2017)

IFN-λ4: The Paradoxical New Member of the Interferon Lambda Family

Por O'Brien, Thomas R., Prokunina-Olsson, Ludmila, Donnelly, Raymond P.
Publicado em 2014

Beasley’s 1981 paper: The power of a well-designed cohort study to drive liver cancer research and prevention

Por Koshiol, Jill, Liu, Zhiwei, O’Brien, Thomas R., Hildesheim, Allan
Publicado no Cancer Epidemiol (2018)

Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C

Por O'Brien, Thomas R., Lang Kuhs, Krystle A., Pfeiffer, Ruth M.
Publicado no Open Forum Infect Dis (2014)

Lymphocyte subsets in hemophilic patients with hepatitis C virus infection with or without human immunodeficiency virus co-infection: a nested cross-sectional study

Por Zhang, Mingdong, O'Brien, Thomas R, Kopp, William C, Goedert, James J
Publicado em 2005

Re: Pearlman and Ehleben - Hepatitis C Genotype 1 Virus with Low Viral Load and Rapid Virologic Response to Peginterferon/Ribavirin Obviates a Protease Inhibitor

Por Wang, Alan S., Pfeiffer, Ruth M., Morgan, Timothy R., O'Brien, Thomas R.
Publicado em 2014

No Scientific Basis to Restrict 8 Weeks of Treatment with Ledipasvir/Sofosbuvir to Patients with HCV RNA <6,000,000 IU/ml

Por O’Brien, Thomas R., Feld, Jordan J., Kottilil, Shyam, Pfeiffer, Ruth M.
Publicado no Hepatology (2015)

Shortening the duration of therapy for chronic hepatitis C infection

Por Emmanuel, Benjamin, Wilson, Eleanor M, O’Brien, Thomas R, Kottilil, Shyam, Lau, George
Publicado no Lancet Gastroenterol Hepatol (2017)

Meeting Overview: Interferon Lambda—Disease Impact and Therapeutic Potential

Por O'Brien, Thomas R., Young, Howard A., Donnelly, Raymond P., Prokunina-Olsson, Ludmila
Publicado no J Interferon Cytokine Res (2019)

Race or Genetic Makeup for HCV Treatment Decisions?

Por O’Brien, Thomas R., Kottilil, Shyam, Feld, Jordan J., Morgan, Timothy R., Pfeiffer, Ruth M.
Publicado no Hepatology (2017)